Abrupt evolution of Philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome

Akiko Fukunaga1, Hiroto Sakoda, Yoshihiro Iwamoto

  • 1Kitano Hospital The Tazuke Kofukai Medical Research Institute, Osaka, Japan.

Insights

This study details a rare case of Philadelphia chromosome-positive acute myeloid leukemia evolving from low-risk myelodysplastic syndrome. Treatment with nilotinib achieved a hematological response and eliminated the Philadelphia chromosome.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myelodysplastic syndrome (MDS) is a clonal stem cell disorder with a ~30% progression rate to acute myeloid leukemia (AML).
  • Clonal evolution in MDS involves genetic aberrations, but the Philadelphia chromosome (Ph) is rarely reported.
  • Philadelphia chromosome-positive AML is a distinct subtype, typically not arising from MDS.

Observation:

  • A 76-year-old man with MDS and refractory neutropenia developed AML after 1.5 years.
  • Peripheral blood and bone marrow showed immature basophils and myeloblasts, with multilineage dysplasia.
  • Cytogenetic analysis revealed the Philadelphia chromosome translocation, t(9;22)(q34;q11).

Findings:

  • The case presented as Philadelphia chromosome-positive AML with basophilia, evolving from low-risk MDS.
  • The patient achieved a hematological response and Ph chromosome clearance with nilotinib treatment.
  • This represents a rare clinical course of MDS progression.

Implications:

  • Highlights the importance of cytogenetic analysis in MDS progression, even in low-risk cases.
  • Suggests that Philadelphia chromosome-positive AML can arise from MDS clonal evolution.
  • Nilotinib shows efficacy in treating Ph-positive AML emerging from MDS.